[Clinical studies on SM-4300, a new human gammaglobulin preparation for intravenous use in pediatrics].

Abstract

Six cases of severe infections in pediatrics, which showed no or insufficient responses to treatment with antibiotics, were treated with additional intravenous infusion of SM-4300. Results were as follows. Three cases of bacterial infections with high fever, showing no response to chemotherapy, were treated with SM-4300, (68-135 mg/kg). Administration of SM-4300 resulted in defervescence, decreasing pain and swelling and showing a trend for improvement in CRP values. Administrations of SM-4300 (61-100 mg/kg) against pleurisy caused by Mycoplasma were effective in defervescence and improvement in chest findings. Clinical effects of SM-4300 were excellent in 2 cases, good in 3 and fair in 1. In this study, no clinical side reactions nor abnormal laboratory values in blood, liver or renal functions were observed.

• Authors: S Nakazawa, H Sato, A Narita, H Suzuki, S Nakazawa, H Chikaoka, K Tazoe, R Koido
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 38 Issue 9 Pg. 2577-86 (Sep 1985) ISSN: 0368-2781 [Print] Japan
• PMID: 4079023 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Immunoglobulins
• SM-4300

Topics

• Anti-Bacterial Agents (administration & dosage)
• Bacterial Infections (therapy)
• Child
• Child, Preschool
• Drug Evaluation
• Drug Resistance, Microbial
• Drug Therapy, Combination
• Female
• Humans
• Immunization, Passive
• Immunoglobulins (administration & dosage)
• Infant
• Infusions, Parenteral
• Male
• Mycoplasma Infections (therapy)